RT @KDAO2011: Potential new target anti-BDCA2 Ab, #litifilimab targets pDC⦠impressive phase 2 studies with sig improv
Tweet Content
Potential new target anti-BDCA2 Ab, #litifilimab targets pDC… impressive phase 2 studies with sig improvement in CLASI-A scores #EULAR2022 @rheumnow https://t.co/hJGx3c3Fbb
Show on Archive Page
On
Display in Search Results
On
PDQ
Off